首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   18846篇
  免费   1272篇
  国内免费   43篇
耳鼻咽喉   106篇
儿科学   764篇
妇产科学   525篇
基础医学   2393篇
口腔科学   273篇
临床医学   3564篇
内科学   3238篇
皮肤病学   261篇
神经病学   1607篇
特种医学   470篇
外科学   1608篇
综合类   182篇
一般理论   47篇
预防医学   2639篇
眼科学   260篇
药学   1140篇
中国医学   44篇
肿瘤学   1040篇
  2023年   119篇
  2022年   173篇
  2021年   355篇
  2020年   286篇
  2019年   417篇
  2018年   494篇
  2017年   376篇
  2016年   401篇
  2015年   434篇
  2014年   627篇
  2013年   1020篇
  2012年   1287篇
  2011年   1574篇
  2010年   792篇
  2009年   703篇
  2008年   1423篇
  2007年   1313篇
  2006年   1311篇
  2005年   1299篇
  2004年   1262篇
  2003年   1113篇
  2002年   1069篇
  2001年   144篇
  2000年   106篇
  1999年   163篇
  1998年   233篇
  1997年   174篇
  1996年   154篇
  1995年   126篇
  1994年   115篇
  1993年   111篇
  1992年   95篇
  1991年   67篇
  1990年   80篇
  1989年   73篇
  1988年   53篇
  1987年   46篇
  1986年   39篇
  1985年   47篇
  1984年   47篇
  1983年   50篇
  1982年   71篇
  1981年   65篇
  1980年   45篇
  1979年   29篇
  1978年   40篇
  1977年   19篇
  1975年   20篇
  1974年   13篇
  1973年   12篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.

Objective

To examine whether a healthy weight intervention embedded in the Parents as Teachers (PAT) home visiting program, which was previously found to improve mothers’ body mass index (BMI) and obesity-related behaviors, changed the BMI of preschool children or maternal feeding practices.

Methods

This stratified randomized trial included preschool-aged children at risk for overweight whose mothers were overweight or had obesity (n?=?179). The Healthy Eating and Active Living Taught at Home (HEALTH) intervention was based on the Diabetes Prevention Program. Differences were examined using repeated-measures mixed-ANOVA models.

Results

Compared with PAT usual care, the HEALTH intervention had no effect on children's BMI or maternal feeding practices. However, combined analyses showed that children's BMI percentile decreased (P??=?.007), BMI z-scores were maintained (P??=?.19), and 3 of 8 feeding practices improved over time (P < .05).

Conclusions and Implications

Additional research is needed to assess the effectiveness of PAT to prevent preschool-age obesity using rigorous designs (eg, group-randomized trials) and to identify its active components. HEALTH is ready to be scaled up to prevent maternal weight gain through embedding within the national PAT program.  相似文献   
2.
3.
Lessons Learned
  • The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
  • Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
  • The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
BackgroundThe RAS/RAF/MEK/ERK signaling pathway is associated with proliferation and progression of hepatocellular carcinoma (HCC). Preclinical data suggest that paradoxical activation of the MAPK pathway may be one of the resistance mechanisms of sorafenib; therefore, we evaluated trametinib plus sorafenib in HCC.MethodsThis was a phase I study with a 3+3 design in patients with treatment‐naïve advanced HCC. The primary objective was safety and tolerability. The secondary objective was clinical efficacy.ResultsA total of 17 patients were treated with three different doses of trametinib and sorafenib. Two patients experienced dose‐limiting toxicity, including grade 4 hypertension and grade 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin over 7 days. Maximum tolerated dose was trametinib 1.5 mg daily and sorafenib 200 mg twice a day. The most common grade 3/4 treatment‐related adverse events were elevated AST (37%) and hypertension (24%). Among 11 evaluable patients, 7 (63.6%) had stable disease with no objective response. The median progression‐free survival (PFS) and overall survival (OS) were 3.7 and 7.8 months, respectively. Phosphorylated‐ERK was evaluated as a pharmacodynamic marker, and sorafenib plus trametinib inhibited phosphorylated‐ERK up to 98.1% (median: 81.2%) in peripheral blood mononuclear cells.ConclusionTrametinib and sorafenib can be safely administered up to trametinib 1.5 mg daily and sorafenib 200 mg twice a day with limited anticancer activity in advanced HCC.  相似文献   
4.
5.
6.

Introduction

Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.

Innovation

An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.

Outcomes

A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.

Comments

We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号